Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of IBB0979 in advanced or metastatic solid tumors
CTR20230877Phase 2Active
- Sponsor
- SUNHO BioPharmaceutical
- Start
- Jul 2023
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of IBB0979 in Nonhematologic neoplasms, sponsored by SUNHO BioPharmaceutical. Started Jul 2023; status: active.
02
Drugs
IBB0979
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20230877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230877.